Physician profile
Robert Mccord
NPI 1730264920
$4,934.57
in general payments reported to CMS, 2019-2025
38 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $189 · 2021: $175 · 2022: $535 · 2023: $1,034 · 2024: $1,256 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,724.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,461.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $584.74 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $505.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $488.10 | 2021-2025 | |
| Lilly USA, LLC | $376.63 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.30 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $152.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $145.46 | 2022-2025 | |
| Amgen INC. | $137.27 | 2021-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $133.72 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $101.79 | 2022-2024 | |
| Amarin Pharma, INC. | $71.25 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $63.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $48.62 | 2022-2025 | Arexvy, Shingrix |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mccord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.